1Bloch Y, Mendlovic S, Strupimky S, et al. Injections of depot antipsychotic medications in patients suffering from schizophrenia: do they hurt? J Clin Psychiatry, 2001; 62 (11): 855-859.
2Patel MX, Nikolaou V, David AS. Psychiatrists' attitudes to maintenance medication for patients with schizophrenia. Psychol Med. 2003; 33 (1) : 83-89.
3Kane JM. Strategies for improving compliance in treatment of schizophrenia by using a long-acting formulation of an anfipsychotic: clinical studies. J Clin Psychiatry, 2003; 64 (Suppl 16) : 34-40.
4Stein R, Preisman O, Alfici S, et al. A long-acting second generation anti-psychotic-experience in Israel. Harefuah. 2004; 143 (6): 408-409.
5Edwards NC, Rupnow MF, Pashos CL, et al. Cost-effectiveness model of long-acting risperidone in schizophrenia in the US. Pharmacoeconomics, 2005; 23 (3): 299-314.
6Treloar A, Beats B, Philpot M. A pill in the sandwich: Covert medication in food and drink. Journal of the Royal Society of Medicine, 2000; 93 : 408-411.
7Srinivasan TN, Thara R. Management of medication noncompliance in schizophrenia by the families in India. Schizophrenia Bulletin, 2002; 28 (3): 531-535.
8Eaddy M, Grogg A,Locklear J. Assessment of compliance with antipsychotic treatment and resource utilization in a medical population. Clin Ther. 2005; 27 (2): 263-272.
9Misdrahi D, Llorca PM, Lancon C, et al. Compliance in schizophrenia: predictive factors, therapeutical considerations and research implications. Encephale. 2002; 28 (3): 266- 272.
10Glick ID, Berg PH. Time to study discontinuation, relapse, and compliance with atypical or conventional antipsychotics in schizophrenia and related disorders. Int CAin Psychopharmacol. 2002; 17 (2): 65-68.
